Amgen
AMGN
Performance
About Amgen
Amgen is a global biotechnology company dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for serious illnesses. The company operates worldwide across multiple therapy areas, including oncology, cardiovascular/metabolic, bone health and inflammation, and emphasizes science-driven approaches to improve patient outcomes. Amgen emphasizes research and development, manufacturing excellence, and responsible innovation as core to its mission. Headquartered in the United States, it maintains a broad global presence and engages in clinical trials, manufacturing, and patient safety initiatives around the world.
Recent News
#JPM26: Day 2 at the JP Morgan Healthcare Conference
Amgen Ends Partnership with Kyowa Kirin on Immunology Drug, Despite Phase 3 Wins
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-Cell Engager Therapy
The Next Generation of GLP-1 Drugs: And How They’ll Reshape Food and Beverage Again
Pharma and Biotech Layoffs 2026 Watch
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Senju Launches First-in-Class Dry Eye Disease Drug in Japan
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
Amgen’s Lung Cancer Drug Tarlatamab Wins China Approval
29 Exciting Companies Hiring Professionals in 2026
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Strategy Pivot Hits GoodRx
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Proteasomes: A Novel Approach to Target the Immune System
Korea’s Ildong Promotes Chae Joon Lee to Co-CEO
Tenpoint Wins FDA Nod for Combination Presbyopia Eye Drop
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Report Says MSD Is in Talks to Buy Revolution Meds
9 Companies Hiring Now in Pennsylvania
FDA Seeks Withdrawal of Amgen's Tavneos, Company Says It Won't Pull Drug
As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ Ready to Reshore
Amgen, Zai Lab Team up on DLL3; Janux Gets $35M Milestone Payment
11 Companies Hiring Manufacturing Professionals Now
Hiring Outlook: February Brings First YOY Job Increase Since 2022
Office of Prescription Drug Promotion (OPDP) News
Amgen Makes up to $840M Cancer Play With Dark Blue Takeover
10 Companies Hiring IT Professionals Now
Abivax Climbs on Lilly Takeover Speculation
Amgen Acquires UK Biotech Dark Blue Therapeutics
An Opinionated Take on NEJM Highlights for Q1 of 2026
Subcutaneous Tepezza Demonstrates Phase III Efficacy in Thyroid Eye Disease
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
TrumpRx List Grows To 54 Drugs, Many Nearing End Of Exclusivity
Teva Intensifies Biosimilar Competition with FDA Approval and Dual Filing Acceptance in US and Europe
Pig Liver Xenotransplant Shows Promise, but More Work Remains
Hengrui, Kailera Tout Positive Results for Dual-Acting Obesity Pill
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
The Biopharma Senior Associate Whose Career Was Fuelled by FUEL
Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
EMA Looks Into 'Data Integrity' Issue with Amgen's Tavneos
Kyowa Kirin Abandons Touted Eczema Drug Following Safety Review
The Next Cambridge? LA Sets Its Sights Higher
Asking Amgen to Withdraw Tavneos, FDA Revisits Years-Old Data Issue
Amgen Gives up on Its Once-Prized Eczema Drug
Amgen Pipeline’s Next Growth Cycle: Replacing Its Old Blockbusters
Tozorakimab Scores Double Win in Phase III COPD Trials
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory
